Biomarkers and Precision Medicine Community (BPMC)

 View Only

OSD on Preclinical Immunogenicity Support and S6 Guidance Interpretation, Oct 30th, 12-1 pm EST

  • 1.  OSD on Preclinical Immunogenicity Support and S6 Guidance Interpretation, Oct 30th, 12-1 pm EST

    Community Leadership
    Posted 09-25-2024 23:55

    Please join for an Open Scientific Discussion (OSD) hosted by the AAPS Biomarkers and Precision Medicine (BPM), Therapeutic Protein Immunogenicity (TPI) and Bioanalytical (BA) Communities on October 30th, 12 – 1 pm EST on the following topic:

     

    Preclinical Immunogenicity Support and S6 Guidance Interpretation

    • Immunogenicity Assessment in Preclinical Species to Support IND?  How critical is the ADA data to support global submissions?
    • Should an Immunogenicity assay be ready to support?  Can such assay be qualified rather than validated?
    • Can toxicology study reports be submitted without ADA data if the findings can be interpreted with changes in PK/PD?
    • What is the practice among different sponsors? Some scenarios may include no ADA performed and rely on impact on PK/PD changes or planned but trigger-based to explain safety findings vs generate all ADA data?
    • Decision tree to define when and under what circumstances ADA assays are developed and validated.
    • Risk mitigation strategies that have been used by some sponsors

    Moderator:

    ·        Vibha Jawa

    Panelists:

    ·        Ellen-Marie Koehler-Stec       [email protected]

    ·        Lauren Stevenson                  [email protected]

    ·        David G Waters                      [email protected]

    ·        Laurent Malherbe                   [email protected]

    ·        Luo, Lina                                 [email protected]

    ·        Starcevic Manning, Marta      [email protected])

    ·        Michael Partridge                   [email protected]

    ·        Gerry Kolaitis                          [email protected]

    ·        Jacob Lesniak                         [email protected]

    ·        Jeannine Bussiere                  [email protected]

    ·        Tong-yuan Yang                     [email protected]

    Organized by:  Vibha Jawa (BMS), Karen Quadrini (Prothena Biosciences), Carmen Fernández-Metzler (PharmaCadence)

     

    We start at 12:00 EST sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

    (Please remain on mute unless asking questions)

     

    When: Wednesday, Oct. 30, 2024 12pm – 1pm EST

    WherePlease join from your computer, tablet or smartphone.
    https://global.gotomeeting.com/join/305789893

    You can also dial in using your phone.
    United States: 
    +1 (872) 240-3412
    Access Code: 305-789-893

    Join from a video-conferencing room or system.
    Dial in or type: 
    67.217.95.2 or inroomlink.goto.com
    Meeting ID: 305 789 893
    Or dial directly: 
    [email protected] or 67.217.95.2##305789893

    New to GoToMeeting? Get the app now and be ready when your first meeting starts:
    https://global.gotomeeting.com/install/305789893

     

    Please feel free to share with colleagues who may be interested in this topic.

     

    Thanks,

    On Behalf of The AAPS BPM, TPI and BA Community Leadership Tea



    ------------------------------
    Carmen Fernandez-Metzler Ph.D.
    President
    PharmaCadence Analytical Services, LLC
    Hatfield PA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------